TY - BOOK AU - Fassi-Fehri, O. ED - Académie Hassan II des sciences et techniques TI - Frontiers in Science and Engineering: International Journal : Life Sciences (Médecine, Health, Agriculture, Biology, Genetics) T2 - Académie Hassan II des sciences et techniques U1 - 616.994 22 PY - 2019/// CY - Rabat PB - Académie Hassan II des sciences et techniques KW - Maroc KW - Médecine KW - Health KW - biology KW - Cancer KW - Tumeur N1 - Combating Cancer: New Approaches through Improved Diagnosis and Immunotherapy Albert SASSON The Rising World of MicroRNAs: Oncogenes and Tumor Suppressors in Cancer Fadila GUESSOUS, Ying ZHANG and Roger ABOUNADER Molecular characterization of triple negative breast cancers: potential application for targeted therapy Giovanna CHIORINO The Molecular Basis of Viro-Induced Carcinogenesis Mohammed EL MZIBRI, Imane CHAOUI, Meriem KHYATTI and Mohammed ATTALEB Assessment of Molecular Biomarkers for Bladder Cancer Diagnosis, Grading and Prognosis Hajar AHANIDI, Chaimae HAFIDI ALAOUI, Mounia BENSAID, Mohammed EL MZIBRI, Ahmed AMEUR, Mohammed ABBAR, Abderrahmane AL BOUZIDI and Mohammed Attaleb Evaluation of GPX1 Pro198Leu Polymorphism, GSTP1 Expression and Gene Promoter methylation in Moroccan patients with Bladder Cancer Khaoula HADAMI, Nadia DAKKA, Mounia BENSAID, Ahmed AMEUR, Hafsa CHAHDI, Mohamed OUKABLI, Abderrahmane AL BOUZIDI, Mohammed ATTALEB and Mohammed EL MZIBRI Epidermal Growth Factor Receptor Mutational Profile in Lung Cancer Moroccan Cohort Houda KAANANE, Hicham EL ATTAR, Amal LOUAHABBI, IGOT CASA, Hind BERRADI,Hind HASSANI IDRISSI, Meriem KHYATTI, Sellama NADIFI Expression Profile of Breast Cancer in Moroccan Women Salah Eddine AYOUBI, Paola OSTANO, Maurizia MELLO-GRAND, Ilaria GREGNANIN,Mohamed ELKARROUMI, Giovanna CHIORINO and Sellama NADIFI Comparative Study of Clinicopathological Features and Prognostic in Triple Negative and Non-Triple Negative Breast Cancer in the North of Morocco Touria DERKAOUI, Mohamed MANSOURI, Joaira BAKKACH, Mohamed FIHRI,Ali LOUDIYI, Amina BARAKAT, Naima GHAILANI NOUROUTI and Mohcine BENNANI MECHITA N2 - Cancer is a major public-health problem in Africa. However the advances made in the treatment of these range of diseases over the past decade are hopeful and the emergence of targeted therapies has changed the evolution of some cancers, known to have a poor prognosis. These therapies have a very high cost which makes them out of reach of the majority of patients in developing countries. There are typically three main types of cancer treatment through surgery, radiotherapy and chemotherapy. The latter is undoubtedly saving lives but at the cost of significant toxicity. The risk of toxicity associated with chemotherapy must therefore be weighed against the risk of cancer progression due to the discontinuation of systemic therapy. Thanks to precision medicine, a revolution is also in progress. Targeted therapies are thus currently carried out and help understanding the mechanisms of cancer-cell function. Targeted therapy uses a “selective” drug that attacks cancer cells by spotting a specific target. This target can be a receptor, a gene or a protein, and the targeted action must intervene at a precise stage of the development of the tumor cell, protecting as much as possible the healthy cells. Targeted therapy is mainly involved in signal transduction pathways, which controls cell multiplication. The so-called tyrosine kinase pathway is the best known up to date. Monoclonal antibodies or enzymatic inhibitors can block this pathway. By acting on specific receptors, these drugs can block the growth of cancer cells, by preventing the tumor from inducing its own vascularization; or they can stimulate the immune system of the patient against cancer cells. Also should be mentioned the recently approved immunotherapy treatment of non small-cell metastatic bronchial-cell cancers. Targeted therapy can also control cancer-cell death, enhancing apoptosis or the natural death of the cell. Some products are being developed for the treatment of cancers of the upper aero-digestive tract (head and neck). These are examples of targeted therapies, being tried and used up to date and which have significantly improved the treatment of cancers. This was the focus of the three-day Summer School (16-18 July 2018), organized by the Hassan II Academy of Science and Technology (Life Sciences and Biotechnology section), in close cooperation with the Al Akhawayn University at Ifrane, Morocco. The program also aimed to the discuss the situation in Morocco and Africa, as well as on how to make the new therapies available to the patients. The participants in the summer school included, in addition to renowned experts from Morocco, Africa and other countries, 15 young researchers (including two from Africa) and 25 senior researchers from various Moroccan institutions. This special issue of Frontiers in Science and Engineering includes eight articles or presentations of from this summer school. A. Sasson, S. Nadifi, A. Filali-Maltouf and C. Martínez Alonso Members of the Life Sciences and Biotechnology Section UR - https://revues.imist.ma/index.php/fsejournal/issue/viewIssue/1730/604 ER -